Ye, Dingwei
Desai, Jayesh
Shi, Jingwen
Liu, Si-Yang Maggie
Shen, Wei
Liu, Tengfei
Shi, Yang
Wang, Dan
Liang, Liang
Yang, Silu
Ma, Xiaopeng
Jin, Wei
Zhang, Pei
Huang, Ruiqi
Shen, Zhirong
Zhang, Yun
Wu, Yi-Long
Funding for this research was provided by:
BeiGene
Article History
Received: 18 October 2022
Accepted: 16 February 2023
First Online: 7 March 2023
Declarations
:
: Ethical approval was obtained from the relevant institutional review boards and all procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients.
: Not applicable.
: D. Ye and SY. Liu report no conflicts of interest. J. Desai reports grants, personal fees, and non-financial support from BeiGene, grants from Roche/Genentech Bristol-Myers Squibb, Novartis, AstraZeneca, grants and personal fees from Amgen, personal fees and other from Pierre-Fabre, outside the submitted work. J. Shi, W. Shen, T. Liu, Y. Shi, D. Wang, L. Liang, S. Yang, X. Ma, W. Jin, P. Zhang, R. Huang, Z. Shen, and Y. Zhang are employees of BeiGene. YL. Wu reports grants from AstraZeneca, Bristol-Myers Squibb and Pfizer and Honoraria for lectures from AstraZeneca Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lily, Jiangsu Hengrui Medicine, MSD, Pfizer, Sanofi, and Roche.This study was sponsored by BeiGene, Ltd.